HIF-1 alpha antibody | knockout validation | Abcam ab179483

This is a knockout-validated antibody summary, based on the publication "HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signaling pathway with positive feedback under hypoxia", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

HIF-1 alpha antibody | knockout validation | Abcam ab179483 figure 1
Figure 1. Immunofluorescence confirmed the successful knockout (KO) of HIF1α in HIF1α-KO and HIF1α/HIF2α-KO cells. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Abcam

Antibody: HIF-1 alpha

Catalog number: ab179483

HIF-1 alpha antibody | knockout validation | Abcam ab179483 figure 2
Figure 2. Western blot shows there were no differences in HIF1α and HIF2α between the control and empty vector groups after culturing both cells in 1% O2 for 72h. However, the expression of HIF1α increased significantly after knocking out HIF2α; and HIF2α expression increased significantly after knocking out HIF1α. From [1].

Summary: Rabbit monoclonal antibody against a recombinant fragment of HIF-1a. Reacts with mouse, rat and human. Predicted to work with sheep, rabbit, cow, ferret, and non human primates. Suitable for western blot and immunocytochemistry/immunofluorescence.

Validation Method

Western blot | Immunocytochemistry

Sample

Control and HIF-1a-KO glioblastoma (GBM) primary cells.

Primary incubation

WB: 1:1,000 dilution.

ICC: 1:100 dilution.

References
  1. Wang P, Zhao L, Gong S, Xiong S, Wang J, Zou D, et al. HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia. Cell Death Dis. 2021;12:312 pubmed publisher